External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology APAO 2023
Roche and Genentech at

APAO 2023

February 23 - February 26
Kuala Lumpur, Malaysia
apaophth.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
01:00 PM
Duration 5mins Kuala Lumpur, Malaysia
View the APAO symposium on "Advancing the management of DME via Ang-2/VEGF-A dual inhibition"
Ngah NF, Yoon YH, Ghanchi F, and Murata T
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:12 PM
Duration 6mins Meeting Room 410 (Level 4)
Key Clinical Pearls for Evaluating Surgical Candidates, and Patient Preference, for the Port Delivery System With Ranibizumab
Chang A, Figueroa M, Holekamp N, Bobbala A, Menezes A, Heinrich D
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:18 PM
Duration 6mins Meeting Room 410 (Level 4)
Faricimab▼ in Neovascular Age-Related Macular Degeneration: Year 1 Results With Week 12 Fluid Data From the Phase 3 TENAYA and LUCERNE Trials
Cheung G, Guymer R, Souverain A, Yang M, Kotecha A, Margaron P
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:24 PM
Duration 6mins Meeting Room 410 (Level 4)
VOYAGER: A Real-world Study of Faricimab▼ and the Port Delivery System With Ranibizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
Chaikitmongkol V, Scheidl S, Bengus M, Guymer R, Koh A
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:30 PM
Duration 6mins Meeting Room 410 (Level 4)
Key Surgical Pearls for Best Practice During the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure
Yoon YH, Wieland M, Jaycock P, Menezes A, Singh N, Malhotra V
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:36 PM
Duration 6mins Meeting Room 410 (Level 4)
Port Delivery System Long-term Portal Extension Data: Three-Year Follow-up From the Phase 3 Archway Study
Hwang DK, Regillo C, Cavichini Cordeiro M, Blotner S, Jaycock P, Gune S
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:00 AM
Duration 5mins Kuala Lumpur, Malaysia
View the APAO symposium on "Expert insights: Continuous delivery of anti-VEGF for the management of nAMD and DME"
Chang A, Cheung G, and Okada M
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema - Diabetic Retinopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:00 PM
Duration 5mins Kuala Lumpur, Malaysia
View the APAO symposium on "Advancing the management of nAMD via Ang-2/VEGF-A dual inhibition"
Fong K, Cheung G, Yanagi Y, and Singer MA
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:30 PM
Duration 6mins Meeting Room 410 (Level 4)
Design and Rationale of the SALWEEN Trial: A Phase 3b/4 Study of Faricimab▼, a Dual Angiopoietin-2 and Vascular Endothelial Growth Factor-A Inhibitor, in Patients With Polypoidal Choroidal Vasculopathy
Lee WK, Iida T, Cheung G, Ruamviboonsuk P, Margaron P, Lai T
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:36 PM
Duration 6mins Meeting Room 410 (Level 4)
Faricimab▼ in Neovascular Age-Related Macular Degeneration (nAMD): Year 2 Patient Case Profiles From the Phase 3 TENAYA/LUCERNE Trials
Chen S, Koh A, Swaminathan B, Patel V, Margaron P, Kotecha A
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:42 PM
Duration 6mins Meeting Room 410 (Level 4)
Durable Vision Gains and Greater Fluid Control With Extended Faricimab▼ Dosing Up to Every 16 Weeks Over 2 Years of Phase 3 YOSEMITE and RHINE Trials in DME
Lai T, Wong T, Jaffe GJ, Gerendas BS, Camino A, Tang Y, Haskova Z
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.